Tom 14, Nr 4 (2019)
Niewydolność serca
Opublikowany online: 2019-08-31
Wyświetlenia strony
479
Wyświetlenia/pobrania artykułu
1756
Empagliflozyna w niewydolności serca — nowe fakty. Komentarz do artykułu: Przerwa w terapii empagliflozyną u pacjenta z HFrEF i hospitalizacja z powodu zaostrzenia HF. Folia Cardiol. 2019; 14(2): 199–205
DOI: 10.5603/FC.2019.0096
Folia Cardiologica 2019;14(4):418-419.
Streszczenie
Brak
Referencje
- Komorowska A, Lelonek M. Przerwa w terapii empagliflozyną u pacjenta z niewydolnością serca z obniżoną frakcją wyrzutową i hospitalizacja z powodu zaostrzenia niewydolności serca. Folia Cardiol. 2019; 14(2): 199–205.
- Ponikowski P, Voors A, Anker S, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016; 18(8): 891–975.
- Zinman B, Wanner C, Lachin J, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117–2128.
- Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019; 139(11): 1384–1395.
- Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018; 138(17): 1904–1907.
- Claggett B, Lachin JM, Hantel S, et al. Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease. Circulation. 2018; 138(15): 1599–1601.
- Patorno E, Pawar A, Franklin JM, et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation. 2019; 139(25): 2822–2830.
- Das SR, Everett BM, Birtcher KK, et al. 2018 ACC Expert Consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018; 72(24): 3200–3223.
- Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019 [Epub ahead of print].
- Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease. Circulation. 2019 [Epub ahead of print]: CIR0000000000000678.
